Literature DB >> 25183038

Concurrent pulmonary thrombosis with systemic embolism: a case report.

Xiao-jie Xie1, Ju-bo Jiang, Jun Jiang, Jian-an Wang.   

Abstract

Based on different mechanisms of blood coagulation, coexistence of venous thromboembolism and arterial thrombosis in a single individual is extremely rare in clinical practice. Both antiplatelet and anticoagulation therapy should be adopted for patients with arteriovenous embolism. Balancing the risk of ischemia and hemorrhage is especially challenging in these patients in order to achieve an optimal clinical benefit. We report on a 55-year-old female with acute pulmonary embolism (PE), subsequently diagnosed as having acute myocardial infarction (AMI) and a cerebral infarction. Examinations had been carried out, excluding potential arteriovenous shunts, cancer, antiphospholipid syndrome and other common hypercoagulable states. A combination of an anticoagulant drug (rivaroxaban, an Xa inhibitor) and an antiplatelet agent (clopidogrel, an ADP receptor inhibitor) was prescribed with a β-blocker and atorvastatin. The embolus was gradually shrunk during the next 10 months, and then it turned back into expanding. During the 16 months' follow-up, an aneurysm of left ventricular apex was found through an echocardiogram and an angiotensin-converting enzyme inhibitor was administered. We conclude that combined anticoagulation and antiplatelet therapy significantly relieved the symptoms and improved the prognosis in patients suffering from arteriovenous embolism without any major clinical bleeding events.

Entities:  

Keywords:  Acute myocardial infarction (AMI); Cerebral infarction; Pulmonary thrombosis; Ventricular aneurysm

Mesh:

Substances:

Year:  2014        PMID: 25183038      PMCID: PMC4162885          DOI: 10.1631/jzus.B1400209

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  12 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Advances in cardiovascular disease: how far is the summit?

Authors:  Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2010-08       Impact factor: 3.066

3.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

4.  Progress and challenges in the cardiovascular field.

Authors:  Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

5.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

6.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

7.  Temporal changes in circulating P-selectin, plasminogen activator inhibitor-1, magnesium, and creatine kinase after percutaneous coronary intervention.

Authors:  Shu-qin Ying; Mei-xiang Xiang; Lu Fang; Jian-an Wang
Journal:  J Zhejiang Univ Sci B       Date:  2010-08       Impact factor: 3.066

Review 8.  Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.

Authors:  Shu Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

9.  Learning on the Web. Case 2: patent foramen ovale (PFO) and paradoxical embolism.

Authors:  Roby D Rakhit
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

10.  Pulmonary embolism incidence and fatality trends in chinese hospitals from 1997 to 2008: a multicenter registration study.

Authors:  Yuanhua Yang; Lirong Liang; Zhenguo Zhai; Hangyong He; Wanmu Xie; Xiaoxia Peng; Chen Wang
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.